Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics

Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects

(2019) Antonio Rampino et al.   Frontiers in Psychiatry

ADAMTS proteins in human disorders

(2018) Timothy J. Mead et al.   MATRIX BIOLOGY

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

(2018) Stefano Aringhieri et al.   PHARMACOLOGY & THERAPEUTICS

Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR

(2018) Susana Llerena et al.   Oncotarget

Exploring the Wnt signaling pathway in schizophrenia and bipolar disorder

(2018) Eva Z. Hoseth et al.   Translational Psychiatry

OUP accepted manuscript

(2018)   CEREBRAL CORTEX

cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia

(2018) Haitao Wang et al.   Frontiers in Molecular Neuroscience

Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT 2A receptor agonism

(2017) Stefano Aringhieri et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy

(2017) Guy Chouinard et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Validation of schizophrenia gene expression profile in a preclinical model of maternal infection during pregnancy

(2017) Juan F. Lopez-Gimenez et al.   SCHIZOPHRENIA RESEARCH

Determination of the substrate repertoire of ADAMTS2, 3, and 14 significantly broadens their functions and identifies extracellular matrix organization and TGF-β signaling as primary targets

(2016) Mourad Bekhouche et al.   FASEB JOURNAL

Glutamate Counteracts Dopamine/PKA Signaling via Dephosphorylation of DARPP-32 Ser-97 and Alteration of Its Cytonuclear Distribution

(2016) Akinori Nishi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Metabotropic glutamate receptors as drug targets: what's new?

(2015) Ferdinando Nicoletti et al.   CURRENT OPINION IN PHARMACOLOGY

Schizophrenia Gene Expression Profile Reverted to Normal Levels by Antipsychotics

(2015) Benedicto Crespo-Facorro et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family

(2015) Richard Kelwick et al.   GENOME BIOLOGY

Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia

(2014) Matthew W. Rice et al.   Brain Structure & Function

Molecular Profiles of Pyramidal Neurons in the Superior Temporal Cortex in Schizophrenia

(2014) Charmaine Y. Pietersen et al.   JOURNAL OF NEUROGENETICS

Molecular Profiles of Parvalbumin-Immunoreactive Neurons in the Superior Temporal Cortex in Schizophrenia

(2014) Charmaine Y. Pietersen et al.   JOURNAL OF NEUROGENETICS

Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt

(2014) Cullen L Schmid et al.   NEUROPSYCHOPHARMACOLOGY

Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials

(2014) Paolo Fusar-Poli et al.   SCHIZOPHRENIA BULLETIN

Recent developments in biased agonism

(2013) James W Wisler et al.   CURRENT OPINION IN CELL BIOLOGY

Inflammatory and immune response genes have significantly altered expression in schizophrenia

(2012) J Sainz et al.   MOLECULAR PSYCHIATRY

Effect of clozapine on the dimerization of serotonin 5-HT2A receptor and its genetic variant 5-HT2AH425Y with dopamine D2 receptor

(2011) Sylwia Łukasiewicz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Extracellular matrix abnormalities in schizophrenia

(2011) Sabina Berretta   NEUROPHARMACOLOGY

Role of beta-arrestin 2 downstream of dopamine receptors in the basal ganglia

(2011) Thomas Del’Guidice   Frontiers in Neuroanatomy

Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I

(2009) R. Miller   Current Neuropharmacology

Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II

(2009) R. Miller   Current Neuropharmacology

The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway

(2009) O. D. Howes et al.   SCHIZOPHRENIA BULLETIN

Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis

(2008) José M. Pelayo-Terán et al.   Early Intervention in Psychiatry